United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - l-phenylalanine - oral capsule - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - l-phenylalanine - oral capsule - 25mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - l-phenylalanine - not applicable - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - l-phenylalanine - oral capsule - 500mg

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ceva animal health pty ltd - phenylalanine-d - unknown - phenylalanine-d amino acid-phenylalanine-d active 0.0 - active constituent

Australia - English - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - gentamicin sulfate, quantity: 1.39 mg/ml (equivalent: gentamicin, qty 1 mg/ml) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections - for the treatment of infections due to one or more susceptible strains of bacteria, including pseudomonas aeruginosa, proteus species (indole positive and indole negative), escherichia coli, klebsiella, enterobacter and serratia species and staphylococcus (including strains resistant to other antibiotics). gentamicin may also be used for the treatment of the following conditions when caused by susceptible organisms: bacteraemia, respiratory tract infections, urinary tract infections, skin and skin structure infections, bone infections, peritonitis, septic abortion and burns complicated by sepsis. aminoglycosides, including gentamicin are generally not indicated in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to less toxic antibiotics. in suspected or documented gram-negative sepsis, gentamicin should be considered for initial antimicrobial therapy. therapy may be instituted before obtaining results of susceptibility tests. the decision to continue therapy is based on results of the susceptibility tests, the severity of the infection and risk toxicity. if anaerobic organisms are suspected, antimicrobial therapy in addition to the gentamicin regimen should be considered.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

21st century products sdn. bhd. - l-phenylalanine -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

nutricia ltd - l-alanine - powder - 1gram/1gram

United States - English - NLM (National Library of Medicine)

professional complementary health formulas - l-phenylalanine 15x, 20x, 30x, 60x, 200x - for the temporary relief of minor muscle or joint pain or inflammation, sadness, irritability, restlessness, or poor concentration.* *claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - sodium acetate trihydrate 2,5 g/1026 ml - eq. sodium acetate 1,5 g/1026 ml; sodium glycerophosphate hydrate - eq. sodium glycerophosphate 1,48 mg/ml; glycine 2,3 mg/ml; glutamic acid 1,64 mg/ml; valine 2,14 mg/ml; arginine 3,31 mg/ml; lysine hydrochloride 3,31 mg/ml - eq. lysine 2,65 mg/ml; leucine 2,3 mg/ml; potassium chloride 1,75 mg/ml; serine 1,33 mg/ml; proline 1,99 mg/ml; alanine 4,68 mg/ml; histidine 1,99 mg/ml; threonine 1,64 mg/ml; tryptophan 0,55 mg/ml; soya oil 38,97 mg/ml; aspartic acid 1,01 mg/ml; glucose monohydrate 107,17 mg/ml - eq. glucose anhydrous 97,43 g/l; calcium chloride dihydrate 0,29 g/1026 ml - eq. calcium chloride 0,22 g/1026 ml; tyrosine 66,25 µg/ml; isoleucine 1,64 mg/ml; methionine 1,64 mg/ml; phenylalanine 2,3 mg/ml; magnesium sulfate 0,47 mg/ml - emulsion for infusion - combinations